Video

Dr. Bekaii-Saab on TAS-102 and Regorafenib in mCRC

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Patients with refractory mCRC go through first- and second-line therapies, and sometimes third-line therapy. The question becomes what to do for patients who progress beyond second-line therapy. In the past, physicians had very few options, if any, for these patients. Now physicians have 2 oral options with regorafenib and TAS-102, says Bekaii-Saab.

These agents are different from each other, though they follow similar pathways. Regorafenib is a multikinase inhibitor, whereas TAS-102 is a more traditional cytotoxic agent that belongs to the family of fluoropyrimidines, explains Bekaii-Saab. It is not 5-fluorouracil or capecitabine, but it belongs to the same family, and can work when those 2 agents fail, states Bekaii-Saab.

Data on these agents come from separate studies—–RECOURSE and CORRECT––that have never been compared head-to-head. What physicians know about their activity comes primarily from their comparison to best supportive care.

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
David Samuel Dicapua Siegel, MD
Moritz Fürstenau, MD
Joseph Franses, MD, PhD